D
espite large investments and expenditures in health care, the United States has consistently ranked poorly on quality outcome measures. 1 There has been a longstanding need for the United States to improve the quality of health care and reduce health care costs. Investing in public health has been 1 proposed way to achieve these goals. Of the $3 trillion spent on health care in the United States in 2014, less than 5% was allocated to public health. 2 Public health infrastructure is focused on improving population health, prevention, and health promotion, providing an essential role for the US health care system. 3 Public health advocates assert that investments should be increased as they potentially yield large returns, both in monetary terms and in health outcomes 3 ; however, there is not consensus in the literature. [4] [5] [6] The Patient Protection and Affordable Care Act (ACA) created the Prevention and Public Health Fund, which increased public health spending with the goal of improving the nation's health and restraining growth in health care costs. 7 However, controversy has surrounded the value and need for this fund, which has resulted in budget cuts and proposed legislation for the complete elimination of the fund. [8] [9] [10] The association between this fund and health outcomes needs to be evaluated to guide policymakers before the fund is further cut or eliminated altogether. Among the areas targeted for health improvement by the Prevention and Public Health Fund is the prevention of health careassociated infections (HAIs). Patients contract HAIs while receiving medical care for an unrelated condition. 11 These infections are among the most common complications associated with hospital care 12 and are a leading cause of preventable death in the United States. 13 Although many HAIs are preventable, these infections negatively affect 1 of every 25 hospitalized patients 14 and are associated with an economic burden of more than $40 billion annually. 15 In 2013, $949 million was dedicated to the Prevention and Public Health Fund, of which nearly half was allocated to the Centers for Disease Control and Prevention (CDC). 16 The CDC then awarded nearly $7 million to 15 state health departments for the Prevention of HAIs Across the Spectrum of Healthcare program. 17 A map of states that received funding for this activity can be found in the Technical Appendix (available as a supplement to the online version of this article at http://www. ajph.org). This activity was unique in that funding was provided to state health departments with action and outcomes expected at the clinical level. 17 State health departments that received the funding implemented evidence-based, multifacility HAI prevention initiatives at health care facilities within their state. 17 Initiatives could range from educational programs on risk factors and routes of transmission to the implementation of monitoring and prevention strategies. 18 We evaluated the association between this Prevention and Public Health Fund activity-the Prevention of HAIs Across the Spectrum of Healthcare program-and the prevention of hospital infections and calculated the return on the investment to inform policymakers of the value of this type of public health funding.
METHODS
This study exploits a natural experiment to evaluate hospital standardized infection ratios (SIRs). We compared SIRs at hospitals in states that received the funding with SIRs at hospitals in states that did not receive the funding, before and after funding allocation. The study period spanned 4 years, including 2 years before funding allocation (2011 and 2012), the year the funding was allocated (2013), and a year when the activity was no longer funded (2014). Because of the prevalence of HAIs and the existence of evidence-based prevention guidelines, the population for this analysis was US acute care hospitals that accept Medicare or Medicaid. The unit of analysis was the hospital.
Data Sources
We collected data from 3 sources. We gathered information on which states received the funding and had a reporting mandate from the CDC's Web site. 17 Centers for Medicare and Medicaid Services (CMS) Hospital Compare data from 2011 to 2014 were the sources for hospital SIRs. 19 To receive payment from Medicare, hospitals must report data about certain HAIs to the CDC's National Healthcare Safety Network, which is then endorsed by the CMS. 19, 20 Hospitals reported data from intensive care units (ICUs), neonatal ICUs, and medical and surgical wards. 19 We retrieved additional hospital control variables from 2011 to 2014 CMS Provider of Services data. 21 We aggregated and analyzed data from all sources at the calendar year level.
Variables
The outcome of interest was the SIR for central line-associated bloodstream infections (CLABSIs). We selected CLABSIs as the primary outcome because the CDC had a standardized and consistent measure for the detection of CLABSIs and mature guidelines about their prevention throughout the study period. 22 The inclusion of other HAIs could lead to discrepancies between facilities and between study years because of the lack of standardization throughout the entire study period. We defined the primary outcome as the annual CLABSI SIR, calculated by dividing the number of observed CLABSI cases in a year by the number of expected CLABSI cases in a year for each hospital. 23 SIRs were not reported for hospitals with less than 1 expected infection in the National Healthcare Safety Network data; however, by using the reported counts for observed and expected cases, we calculated SIRs for these facilities in our analysis. We adjusted the number of expected CLABSI cases for factors that might influence the number of infections, including hospital location, affiliation with a medical school, and bed count. 23 We also added the following covariates to control for hospital characteristics that may be correlated with SIRs: hospital ownership, provision of inpatient surgeries, provision of emergency services, presence of a clinical laboratory on site, presence of an ICU on site, and percentage of registered nurses. In addition to the hospital-level covariates, we included the existence of state reporting mandates to control for the influence of these mandates on reported SIRs independent of the receipt of funding.
Statistical Analysis
We modeled hospital CLABSI SIRs as a function of the control variables using a difference-in-differences specification. 24 We defined hospitals in states that received the funding in 2013 as the "funded" hospitals, and hospitals in states that did not receive the funding in 2013 as the "control" hospitals. We modeled CLABSI SIRs as a function of a dichotomous variable indicating whether the hospital was in a state that received funding ("funding"), a year fixed effect for 2013 ("year 2013") and 2014 ("year 2014"), and interactions between "funding" and "year 2013" and "funding" and "year 2014" to measure the association between the public health funding and the CLABSI SIRs in 2013 and 2014, respectively. We applied a hospital fixed effect to control for all observed and unobserved time-invariant factors. We rejected random effects in favor of fixed effects based on the results of a Hausman specification test (P < .001). 25 The dependent variable, CLABSI SIR, was positively skewed, and thus it was log transformed. Because approximately 40% of hospitals had no observed CLABSIs (i.e., numerator of SIR = 0 and thus SIR = 0), we added 0.0001 to the SIR before log transforming to prevent the omission of those observations.
We tested and confirmed that preperiod trends were parallel between the states that received the funding and the states that did not, using 2 years of data before the funding was allocated (years 2011 and 2012). Parallel preperiod trends imply that the funded and control hospitals were evolving in a similar manner prior to disbursement of the funding. This is a necessary condition for a differencein-differences specification. 24 We accounted for regression to the mean that would occur if funding was disproportionately distributed to facilities with extremely high SIRs before funding allocation to control for the tendency to move closer to the mean through random chance. 26 Lastly, we adjusted the parameter estimates for heteroskedastic smearing, and we calculated the standard errors using a bootstrap with state clustering. 27 State clustering is used because funding was allocated at the state level, but the unit of analysis was the hospital. A detailed description of the model specification can be found in the online Technical Appendix.
We calculated the cost offsets associated with the reduction in infections to determine if they outweighed the initial investment. We calculated reductions in CLABSIs using the parameter estimate percent reduction from the difference-in-differences model. We multiplied the number of infections averted by the hospital cost per CLABSI ($25 135) 28 to compute the cost offsets. We then estimated the return on investment (ROI) by dividing the cost offsets by the investment provided to the 15 states. 29 The analysis assumed that the entire investment was allocated to CLABSI prevention in the hospital setting. We recomputed the infections averted and cost offsets for each bootstrap iteration. This allowed for determination of the expected value and a 95% confidence interval for each of these parameters.
We conducted robustness and specification checks. We refitted the model using a generalized linear model with a log-link function and g distribution to assess the influence of the fixed effect specification. Additionally, to normalize the error variance and determine whether the decline in infections was dominated by large changes in smaller facilities, we applied an analytic weight of the SIR denominator (expected number of cases). The normalized error variance specification is considered a more conservative estimate. We completed statistical analysis with Stata version 13.1 (StataCorp LP, College Station, TX).
RESULTS
Hospitals in states that received funding experienced sharper unadjusted declines in their CLABSI SIR than did hospitals in states that did not receive funding (Table 1) . Additionally, changes in hospital characteristics in hospitals in funded states did not significantly differ from changes over time in hospitals in control states as evidenced by the "Difference-in-Differences" column of Table 1 . Table 2 reports the estimates of the association between the public health funding and CLABSI SIRs in 2013 (year activity was funded) and 2014 (year activity was not funded) from the base-case model that applied a fixed effect, accounted for regression to the mean, and adjusted the estimates for heteroskedastic smearing and bootstrapping. In 2013, the year the activity was funded, states that received the funding experienced a 33.1% reduction in infections (P = .02). In 2014, after the funding for this activity stopped, both funded and nonfunded states experienced a decline in their CLABSI SIRs. A significant difference in CLABSI SIR between funded and nonfunded states was no longer observed in 2014.
The results were robust to the sensitivity analyses. The estimate from a generalized linear model specification was in line with the estimates from the hospital fixed effects specification. The estimate weighted by the frequency of the SIR denominator was reduced to -10.1% (P = .01), suggesting that the unweighted estimates may be influenced by large reductions at smaller facilities. Therefore, we treated this estimate as the lower bound. The results of the sensitivity analyses can be found in the online Technical Appendix. Table 3 reports the expected value and 95% confidence intervals for infections averted, cost offsets, and ROI. When we used the parameter estimate from the base-case specification (-33.1%), the public health funding was associated with a reduction of 1674 CLABSIs in 2013. This reduction yielded cost offsets due to infections averted of greater than $40 million and a positive ROI that ranged from 1.1 to 11.2, or a return of $1.10 to $11.20 for every $1 invested in this activity of the Prevention and Public Health Fund. The ROI calculated by using the estimates from the other model specifications fell within this range. Although the reduction in infections was not sustained after the funding ended, the reduction was large enough in the first year to recoup the investment.
DISCUSSION
The Prevention and Public Health Fund activity-the Prevention of HAIs Across the Spectrum of Healthcare program-was significantly associated with a 33.1% reduction in CLABSI SIRs at hospitals in states that received the funding. The statistical significance of the estimate was robust in the sensitivity analyses, with a parameter estimate range of 10.1% to 36.2% for the year of the funding (2013). There were no longer statistically significant declines associated with the funded activity in 2014, which was the year after the funding ended. These findings are consistent with a study that evaluated funding from the American Recovery and Reinvestment Act specifically devoted to building capacity for HAI prevention at the state level. 30 Targeted funding to state health departments for HAI prevention was associated with significantly greater reductions in CLABSI SIRs in states that received funding compared with states that did not. 30 Even though significant declines in infections associated with the funded activity were not evident when the activity was no longer funded, the number of infections averted in 2013 alone produced cost savings greater than the initial monetary investment, resulting in a positive ROI of 6.2 (range = 1.1-11.2). This ROI is in line with ROIs calculated for other federal investments such as the Clean Air Act and investments in public transportation, which have an ROI of around 4. 28 Our ROI estimate is within the ROI range calculated by a study that evaluated the economic benefits of the CDC's CLABSI prevention efforts over an 18-year period, from 1990 to 2008. 28 That study calculated a range in ROI of 3.88 to 23.85. 28 
Limitations
The reduction in CLABSIs and ROI should be interpreted cautiously, for several reasons. First, the funding targeted multiple infections in multiple health settings, but the analysis was limited to 1 HAI in 1 setting, which may have led to an underestimate of the ROI. We selected CLABSIs as the outcome because of their standardized metrics for detection and mature prevention guidelines. Second, major declines in central-line infections occurred between 2001 and 2009. 22 Therefore, a larger reduction in SIR might have been observed if a higher prevalence HAI was evaluated.
Third, data were not available on how state health departments distributed the funding they received. Therefore, it was not possible to allocate a specific amount of the investment to preventing CLABSIs in the hospital setting. The investment used in the ROI calculation was the entire amount allocated to the Prevention of HAIs across the Spectrum of Healthcare activity. Therefore, the positive ROI is probably an underestimate because the investment dedicated specifically to hospital CLABSIs (denominator of ROI) was probably not the entire investment. Fourth, the returns used in the ROI calculation only included the direct medical cost of a CLABSI. The ROI may have been higher if data on indirect costs, such as reduced productivity, were available for inclusion.
Fifth, a limitation common to many public health value evaluations is that funding is allocated to public health departments often on the basis of greatest need (e.g., prevalence of health problems) or to departments that can develop the best proposals (e.g., those communities with more resources and greater capacity). 31 This source of bias is potentially Note. CI = confidence interval. a A = Adjusted change in infections (from Table 2 reduced by controlling for regression to the mean; however, bias resulting from how the funding was allocated could still exist. Lastly, because the funding was not randomly allocated, caution should be used when generalizing the results to other settings. There were likely contemporaneous initiatives targeting CLABSIs. The specification attempted to control for such initiatives by using the control group of hospitals in states that did not receive funding to provide a benchmark of what would have occurred had the funding not been allocated. Unfortunately, the common shock assumption, or the assumption that events that occur during or after the funding allocation will affect the funded and control states equally, is required for causal inference, but it is not directly testable. 24 For these reasons, the results should not be interpreted as causal.
The perspective of this analysis was from the societal level. In taking that perspective, we evaluated whether the returns in the funded states were greater than the total investment. Future research should limit the perspective to individual states and hospitals to determine what actions were associated with the largest returns. To do this, data on which hospitals the state health departments targeted and how the state health departments used their funding would be needed. This would allow us to attribute the results to those hospitals that did and did not receive funding and determine which activities were associated with the largest reductions in CLABSI and which were sustainable.
Public Health Implications
Resources are best used when allocated to activities with well-defined needs that can be addressed with evidence-based interventions proven to yield a positive health and economic impact. However, evaluative research on the value of public health activities is lacking. Thus, there are ongoing debates about whether public health investments generate a positive return. For other financed health interventions, an evaluation of the consequences of health information technology on health outcomes has been recommended; similarly, large investments into health should be complemented with evaluation. 32 This study provides an evaluation of the association between a funded public health activity and improved health outcomes large enough to generate cost savings. However, public health researchers should continue to expand the evidence base around the value of public health investments to better inform policymakers.
This study found that providing funding to state health departments was associated with a significant reduction in hospital bloodstream infections that yielded a positive return on investment within a 1-year period. This funding allocation saved costs as the improvement in health outcomes outweighed the initial investment. These savings provide important evidence to inform the debate regarding the value of public health funding. However, although the funding reduced hospital infections enough to generate a positive return on investment in the first year, the reduction was not sustained after the activity was no longer funded. One possible explanation for the reductions in CLABSIs observed within the year of the funding is that the funded states already had qualified staff to immediately start implementing the prevention strategies. Furthermore, the lack of sustained improvement could be partially explained by the decrease in CLABSIs observed nationally over time, or it may suggest that ongoing investments are necessary. Funding public health activities of this type should be encouraged, along with close evaluation of benefits and return on investment, as they potentially provide a mechanism to improve population health and reduce health care costs. Additionally, continued and ongoing development of public health support and funding for HAI prevention is encouraged as investments in carefully targeted areas may improve population health and reduce health care costs. 30 These results provide evidence of the health and financial gains associated with a funded public health activity that targeted a single major public health problem occurring in the hospital setting. Further evaluative research on other activities funded through the Prevention and Public Health Fund is encouraged to provide additional evidence of its value.
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